FR167653, a potent suppressant of interleukin-1 and tumor necrosis factor-α production, ameliorates colonic lesions in experimentally induced acute colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 16, Issue 10, 2001, Pages 1105-1111

  Blandino, Ivan I Pacheco ^a   Otaka, Michiro ^a   Jin, Mario ^a   Komatsu, Koga ^a   Odashima, Masaru ^a   Konishi, Noriaki ^a   Sato, Toshihiro ^a   Kato, Sayuri ^a   Watanabe, Sumio ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

Cytokine suppressant; Experimental colitis; Interleukin ; Tumor necrosis factor

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; ACETIC ACID; ARACHIDONIC ACID; CELL ADHESION MOLECULE; CYTOKINE; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; COLITIS; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EVALUATION; INHIBITION KINETICS; MALE; METABOLITE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RAT;

EID: 0034755270     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2001.02584.x     Document Type: Article

References (32)

1. Cytokines in intestinal inflammation. Pathophysiological and clinical considerations
2. The role of cytokines in the pathogenesis of acute pancreatitis
3. Pathogenesis of inflammatory bowel disease
4. Lessons for inflammatory bowel disease from experimental models
5. Inflammatory bowel disease 1999: Present and future promises
6. Tumor necrosis factor a antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
7. Delayed hypersensitivity to infliximab (remicaide) re-infusion after 2-4 year interval without treatment
8. Effect of FR167653 on small bowel ischemia-reperfusion injury in dogs
9. Amelioration of liver damage induced by ischemia and reperfusion with FR167653; A newly synthesized cytokine suppressive anti-inflammatory drug
10. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesion in rats
11. Cytokine suppressive agent improves survival rate in rats with acute pancreatitis of closed duodenal loop
12. A comparative analysis of two models of colitis in rats
13. Octreotide effectively decreases mucosal damage in experimental colitis
14. Non-surgical therapy for ulcerative colitis
15. Cytokine-based therapies in inflammatory bowel disease
16. Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation
17. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shock
18. Animal modes of inflammatory bowel disease-an overview
19. Experimental models of inflammatory bowel disease
20. Tumor necrosis factor-alfa, interleukin-1 beta and interleukin-6 expression in inflammatory bowel disease
21. Enhanced secretion of tumor necrosis factor-alfa, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
22. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease
23. Cytokines in inflammatory bowel disease
24. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis
25. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation
26. Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice
27. Intestinal epithelial cells both express and respond to interleukin 15
28. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells
29. Attenuation of the inflammatory response in an animal colitis model by neutrophil inhibitory factor, a novel β2-integrin antagonist
30. Therapy of inflammatory bowel disease
31. 2 and inflammatory cytokines, human monocytes, and alveolar macrophages in response to endotoxin
32. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases